Seroprevalence of *Strongyloides stercoralis* and Evaluation of Universal Screening in Kidney Transplant Candidates: A Single-Center Experience in Houston (2012–2017)

Mohanad Al-Obaidi,1 Rodrigo Hasbun,1 Karen J. Vigil,1 Angelina R. Edwards,2 Violeta Chavez,3 David R. Hall,4 Wasim A. Dar,4 Aleksandra De Golovine,2 Luis Ostrosky-Zeichner,1 John S. Bynon,4 and Masayuki Nigo1

Divisions of Infectious Diseases, 1Renal Disease and Hypertension, and 2Immunology and Organ Transplantation, and 3Department of Pathology and Laboratory Medicine, McGovern Medical School, University of Texas Health Science Center at Houston

**Background.** Disseminated strongyloidiasis in solid organ transplant recipients is a rare but devastating infection. In our center, we implemented a universal screening of all candidates for kidney transplantation. We assessed the seroprevalence and utility of universal screening for strongyloidiasis in our center.

**Methods.** Patients were identified from our transplant referral list (from July 2012 to June 2017). Demographics, pretransplant laboratory, and serological screenings were retrospectively collected. For *Strongyloides*-seropositive (SSp) patients, data on travel history, symptoms, treatment, and stool ova and parasite examinations were extracted. Logistic regression and multiple imputation for missing data were performed.

**Results.** A total of 1689 patients underwent serological screening, of whom 168 (9.9%) were SSp. Univariate analysis revealed that SSp patients had higher rates of eosinophilia, diabetes mellitus, latent tuberculosis and were likely to be either Hispanic or Asian (*P* < .05). In multivariate analysis, eosinophilia (*P* = .01), diabetes mellitus (*P* = .02), and Asian race (*P* = .03) were associated with being SSp, but 45 (27%) of the SSp patients did not have any of these 3 factors, and 18 SSp patients (11%) had no epidemiological risk factors. All patients received ivermectin, and none developed disseminated strongyloidiasis. Of patients who underwent serological screening on multiple occasions, 6.8% seroconverted while waiting for kidney transplantation.

**Conclusions.** We found a high rate of *Strongyloides* seropositivity among our kidney transplantation candidates. No epidemiological risk factors effectively predicted SSp status in our population, and universal screening identified a large number of patients without such factors. Serial screening should be considered when a long wait time is expected before transplantation.

**Key words:** kidney transplant candidate; pretransplant screening; strongyloidiasis.

*Strongyloides stercoralis* is an intestinal parasite with an estimated 30–100 million infected individuals worldwide, mainly in the tropical, subtropical, and warm temperate regions [1]. In the United States, the prevalence is reported to be <6%, mostly in the southeastern United States and higher among immigrants, yet data in Texas are scarce [1, 2]. The filariform larvae of *S. stercoralis* infect humans by penetrating exposed skin through contaminated soil or through ingestion and are then transported to the lungs through the bloodstream [1–4]. Once fully developed inside the host, they cause a chronic gastrointestinal (GI) infection that persists for several decades with few or no symptoms [3, 5]. In the immunocompromised population, such as solid organ transplant recipients, chronic strongyloidiasis may cause hyperinfection or disseminated diseases, with a high mortality rate, ranging from 50% to 89% [3, 6, 7].

Factors associated with *Strongyloides* infection include alcoholism, steroid use, and human T-cell leukemia virus infection [8–10]. In addition, disseminated infections or hyperinfections have been reported among patients with human immunodeficiency virus [11]. Although the primary cause of disease and death in solid organ transplant recipients is thought to be a reactivation and autoinfection from chronic or latent infection, there are documented reports of donor-derived infections [14, 15].

Solid organ transplant societies currently recommend targeted screening based on patients’ epidemiological risks [16–18]. However, the definition of “endemic region” for strongyloidiasis in the guidelines is unclear. Certain parts of the Appalachian and southeastern United States are considered endemic areas [4, 19]. In Memorial Hermann Hospital renal transplant center in Houston, Texas, after a case of disseminated strongyloidiasis, we instituted a universal (nontargeted) screening for chronic *S. stercoralis* infection using an enzyme-linked immunosorbent
assay (ELISA) for *Strongyloides* antibody, because data regarding the endemicity of *Strongyloides* in our area are scarce and targeted screening may be difficult owing to the blurring between rural and urban populations. The aim of this study was to describe the seroprevalence of *S. stercoralis* among potential kidney transplant recipients and to evaluate the utility of *Strongyloides* universal screening in our center in Houston.

**MATERIALS AND METHODS**

After receiving approval from the institutional review board at the University of Texas Health Science Center at Houston, we obtained patient identification numbers from our kidney transplant referral database for the period of July 2012 to June 2017. All patients referred to our transplant center for renal transplant were screened for *S. stercoralis* infection using commercial ELISA tests. One of 2 ELISA kits was used for screening, depending on the study period: the Bordier-ELISA kit (Bordier Affinity Products) (sensitivity, 83%–89%; specificity, 97%–98%) or the Microwell ELISA kit (SciMedix or New Life Diagnostics) (referred to as IVD-ELISA in published studies [20, 21]; sensitivity, 89%–91%; specificity, 97%–99%), which detect antibodies against *Strongyloides ratti* antigens and *S. stercoralis* larval (L3) antigens, respectively. The blood samples were obtained in our transplant center.

We retrospectively reviewed patients’ demographics, including ethnicity/race, country of origin, transplant type, pretransplantation screening tests for infectious diseases (cytomegalovirus immunoglobulin G, human immunodeficiency virus, syphilis, tuberculosis screening with interferon γ release assay [either QuantIFERON-TB Gold In-Tube or T-SPOT.TB test], and Epstein-Barr virus immunoglobulin G), and the presence of eosinophilia (>0.5 K/mL). For patients with who were seropositive, the presence of GI symptoms, travel history, and treatment type were collected from the medical records. Some patients underwent multiple screenings for *Strongyloides*. In those with positive serological results, we collected data from the time of the positive result, and in those with only negative results, we collected data from the time of the first negative result. However, those multiple serological results were used to identify patients who seroconverted. Furthermore, patients were grouped into *Strongyloides*-seropositive (SSp) and *Strongyloides*-seronegative (SSn) groups.

Descriptive statistics were used to summarize demographic data and clinical characteristics. Continuous variables are presented as mean or median with range, and categorical data as frequency and percentage. Wilcoxon rank-sum tests and χ² or Fisher exact tests were used to compare continuous and categorical variables, respectively. Variables showing a difference in the univariate analysis with a *P* value <.05 were included in the logistic regression model. All tests were 2 sided with a significance level of .05. Bootstrapping was performed to estimate the internal validity of the regression model. Because a significant proportion of SSn patients had missing data for their county of origin, multiple imputation was used to obtain 5 imputed data sets for the supplementary analysis. The imputation model included age, ethnicity/race, diabetes mellitus (DM), eosinophilia, and latent tuberculosis. Data analysis was performed using IBM SPSS Statistics for Windows software, version 24 (IBM).

**RESULTS**

Our center received 2474 referrals for kidney transplantation during the period of July 2012 to June 2017; 1689 (68%) of the patients underwent pretransplantation screening, with 270 patients receiving kidney transplants during the studied period. Since the implementation of the screening and preemptive treatment with ivermectin, we have not encountered any disseminated or hyperinfection strongyloidiasis in our kidney transplant recipients.

Table 1 shows patients’ baseline characteristics, country of origin, comorbid conditions, and pretransplantation serological results. A total of 1689 patients underwent pretransplantation *S. stercoralis* screening, with 617 (36.5%) having multiple *Strongyloides* serological tests performed during the study period. A total of 168 screened patients (9.9%) were SSp; 40 of the 168 underwent kidney transplantation. There was no statistically significant difference between the SSp and SSn groups regarding their median age (52 years) or sex distribution (61% male). Hispanic and Asian patients were more likely to be SSp (*P* = .04), but there was no significant difference in country of origin between the 2 groups. SSp patients were more likely than SSn patients to have DM (108 [64%] vs 828 [54%], respectively; *P* = .01) or eosinophilia (33 [20%] vs 192 [13%]; *P* = .02) and more likely to have a positive result. However, those multiple serological results were used to identify patients who seroconverted. Furthermore, patients were grouped into *Strongyloides*-seropositive (SSp) and *Strongyloides*-seronegative (SSn) groups.

Descriptive statistics were used to summarize demographic data and clinical characteristics. Continuous variables are presented as mean or median with range, and categorical data as frequency and percentage. Wilcoxon rank-sum tests and χ² or Fisher exact tests were used to compare continuous and categorical variables, respectively. Variables showing a difference in the univariate analysis with a *P* value <.05 were included in the logistic regression model. All tests were 2 sided with a significance level of .05. Bootstrapping was performed to estimate the
Only 1 of the 42 patients (2%) who underwent stool ova and parasite tests had a positive stool result for *S. stercoralis* larvae.

All SSp patients were treated before undergoing transplantation. The treatment regimen was available in 92 of the 168 patients (55%), who took 200 μg/kg of ivermectin orally in 2 separate doses; 67 of 92 (72%) took daily doses over 2 consecutive days, and 14 (15%) received 2 doses 1 week apart.

Pretransplantation serological screenings are annually repeated in our center. Of 617 patients who underwent multiple *S. stercoralis* serological tests, 42 (6.8%) seroconverted. Table 4 shows the characteristics of patients who seroconverted from seronegative to seropositive over the observed period. The majority of seroconverted patients were born in the United States (58%), with 3 of them having no history of travel outside the United States.

### DISCUSSION

To our knowledge, this is the largest study that has evaluated the seropositivity and universal (nontargeted) screening for chronic *S. stercoralis* infection among patients referred for a kidney transplant in the United States. We found that 9.9% of the screened kidney transplant candidates in the Houston area were seropositive for *S. stercoralis* infection. In addition, our data suggest that targeted screening for strongyloidiasis may fail to identify a significant proportion of SSp patients in

### Table 1. Baseline Characteristics, Country of Origin, Comorbid Conditions, and Pretransplantation Serological Results in 1689 Solid Organ Transplant Candidates Undergoing Screening for *Strongyloides*

| Characteristic                      | SS (n = 168) | SSn (n = 1521) | P Value |
|-------------------------------------|--------------|---------------|---------|
| Male sex                            | 102/168 (61) | 936/1521 (61) | .84     |
| Age, median (IQR), y                | 52 (41–60)   | 52 (45–60)    | .21     |
| Ethnicity/race                      |              |               |         |
| Hispanic                            | 56/168 (33)  | 426/1521 (28) | .04     |
| Non-Hispanic white                  | 26/168 (16)  | 309/1521 (20) |         |
| African American                    | 45/168 (27)  | 500/1521 (33) |         |
| Asian                               | 9/168 (5)    | 40/1521 (3)   |         |
| Other                               | 32/168 (19)  | 246/1521 (16) |         |
| Country/region of originc           |              |               |         |
| United States                       | 84/145 (58)  | 571/935 (61)  | .12     |
| Mexico, Central/South America, or the Caribbean | 49/145 (34) | 263/935 (28) |         |
| Asia                                | 11/145 (8)   | 59/935 (6)    |         |
| Other                               | 1/145 (1)    | 38/935 (4)    |         |
| Comorbid condition                  |              |               |         |
| Cirrhosis                           | 4/168 (2)    | 43/1521 (3)   | .73     |
| Diabetes mellitus                   | 108/168 (64) | 828/1521 (54)| .01     |
| Hypertension                        | 153/168 (91)| 1323/1521 (87)| .13     |
| HIV infection                       | 4/168 (2)    | 37/1521 (2)   | .96     |
| Type of transplantationd            |              |               |         |
| Kidney                              | 166/168 (99)| 1463/1521 (96.2)| .36     |
| Kidney and pancreas                 | 2/168 (1)    | 47/1521 (3)   |         |
| Pancreas                            | 0            | 1/1521 (0.1)  |         |
| Othere                             | 0            | 10/1521 (0.7) |         |
| Positive pretransplantation serological results |          |               |         |
| Syphilis screening                  | 9/168 (6)    | 88/1521 (6)   | .9      |
| Latent tuberculosis screeningf      | 21/161 (13)  | 107/1432 (8)  | .01     |
| CMV IgG                             | 142/168 (85)| 1198/1521 (79)| .08     |
| EBV IgG                             | 162/163 (99)| 1484/1511 (98)| .40     |
| Hepatitis C screening               | 13/168 (8)   | 98/1521 (6)   | .46     |
| Eosinophilia                        | 33/168 (20)  | 192/1521 (13)| .02     |

Abbreviations: CMV, cytomegalovirus; EBV, Epstein-Barr virus; HIV, human immunodeficiency virus; IgG, immunoglobulin G; IQR, interquartile range; SSn, Strongyloides-seronegative; SSp, Strongyloides seropositive.

*Data represent no./total (%) of patients unless otherwise specified; denominators (totals) vary according to availability of data.

*Significant at *P* < .05.

*Data were missing for a significant number of patients in the SSn group, because their country of origin was not routinely documented.

*The type of transplantation for which patients were referred.

*The “Other” category includes combined transplants (eg, liver and kidney).

*Patients with indeterminate results were excluded from analysis.

(Supplementary Table 1). Only 1 of the 42 patients (2%) who underwent stool ova and parasite tests had a positive stool result for *S. stercoralis* larvae.
our pretransplant population because many of these patients had none of the epidemiological risk factors used in targeted screening.

*S. stercoralis* transmission from a donor has been reported in solid organ transplant recipients. Hamilton et al. [22] reported 2 cases involving kidney transplants in which the donor, who was born in the Dominican Republic, had received steroid therapy before procurement of the organs. There are other published cases reporting donor-derived strongyloidiasis in recipients of intestinal and liver transplantation involving donors coming from endemic areas (Honduras and Ecuador) [14, 23].

A study by the New York Organ Donor Network of targeted screening in donors with previous residential histories in the endemic area, from 2010 to 2013, found that only 10 of 233 consented potential donor (4.3%) were positive at ELISA for *S. stercoralis* antibody against crude antigen [15]. Because 6 of 7 reported donors were born in Latin America, the authors concluded that targeted donor screening can avert donor-derived transmission [15]. However, our data elucidated the difficulty of targeted screening in our population, because a high proportion (22%) of SSp patients were born in the United States and denied any travel histories. Furthermore, 18 SSp patients (11%) and 3 of 16 (19%) who seroconverted (from negative to positive) during the study period did not have any epidemiological risk factors, which indicates that indigenous cases may exist in our area, as shown in a prior report from rural Kentucky’s Appalachian regions, with a prevalence of 1.9% [2].

One of the challenges in chronic strongyloidiasis is the diagnostic methods. Because the microscopical stool examination method has a low yield, serological tests are generally recommended for the screening before the transplantation [17]. However, the sensitivities and specificities vary among different *Strongyloides* serological tests, and there is concern about possible false-positivity. During our study period, we used 2 kinds of ELISA kits (Bordier-ELISA and Microwell ELISA). The use of *S. ratti* larval antigens may have a slightly lower sensitivity because of incomplete cross-reactivity of both *Strongyloides* species. The tests are less specific in the presence of other helminthic infections; however, the ova and parasite examinations did not detect other parasitic infections in our cohort. To improve specificity, different diagnostic platforms as well as new antigens, such as recombinant antigen derived from *S. stercoralis*, have been studied. Among patients with culture- or smear-proven *Strongyloides* infection, a previous study

### Table 2. Travel History, Gastrointestinal Symptoms, and Treatment History in 168 Strongyloides Seropositive Patients

| Characteristics                      | SSp Patients, No. (%) |
|--------------------------------------|-----------------------|
| Travel history                       |                       |
| None                                 | 20/79 (25)            |
| Mexico, Central America, or the Caribbean | 47/79 (60)        |
| Asia                                 | 10/79 (13)            |
| Other                                | 2/79 (3)              |
| Gastrointestinal symptoms            | 14/153 (9)            |
| Abdominal pain                       | 2/153 (1)             |
| Nausea                               | 1/153 (1)             |
| Diarrhea                             | 10/153 (7)            |
| Other                                | 1/153 (1)             |
| Ivermectin treatment regimen         |                       |
| Once daily for 2 d                   | 67/92 (72)            |
| Once weekly for 2 doses              | 14/92 (15)            |
| Other regimen                        | 6/92 (7)              |

Abbreviation: SSp, Strongyloides-seropositive.

*Data represent no./total (%) of patients; denominators (totals) vary according to availability of data.

### Table 3. Baseline Factors Associated With Seropositivity for Strongyloides at Logistic Regression Analysis*

| Characteristic                        | OR (95% CI) | P Value |
|---------------------------------------|-------------|---------|
| Ethnicity/race                        |             |         |
| Hispanic                              | 1.4 (.86–2.4) | .16     |
| Non-Hispanic white                    | Reference   | ...     |
| African American                      | 1.1 (.7–1.9) | .7      |
| Asian                                 | 2.7 (1.1–6.4) | .03*    |
| Others                                | 1.5 (1.1–2.7) | .1      |
| Diabetes mellitus                     | 1.5 (1.1–2.1) | .02*    |
| Eosinophilia                          | 1.7 (1.1–2.7) | .01*    |
| Positive at latent tuberculosis screening | 1.6 (9.2–2.7) | .06    |

Abbreviations: CI, confidence interval; OR, odds ratio.

*Validated by bootstrap analysis.

*Significant at P < .05.

### Table 4. Characteristics of Patients Who Seroconverted After Initially Negative Strongyloides Serological Results

| Characteristics                        | Patients Who Seroconverted to SSp, No. (%)* (n = 42) |
|----------------------------------------|-------------------------------------------------------|
| Male sex                               | 25/42 (59)                                            |
| Age, median (IQR), y                   | 52 (44–58)                                            |
| Ethnicity/race                         |                                                       |
| Hispanic                               | 14/42 (33)                                            |
| Non-Hispanic white                     | 5/42 (12)                                             |
| African American                       | 16/42 (38)                                            |
| Asian                                  | 2/42 (6)                                              |
| Other                                  | 5/42 (12)                                             |
| Country/region of origin               |                                                       |
| United States                          | 19/33 (58)                                            |
| Mexico, Central/South America, or the Caribbean | 11/33 (33) |
| Asia                                   | 2/33 (6)                                              |
| Other                                  | 1/33 (3)                                              |
| Travel history                         |                                                       |
| None                                   | 3/16 (19)                                             |
| Mexico/Central America                 | 11/16 (69)                                            |
| Other                                  | 2/16 (12)                                             |

Abbreviations: IQR, interquartile range; SSp, Strongyloides seropositive.

*Data represent no./total (%) of patients unless otherwise specified; denominators (totals) vary according to availability of data.
indicated that new methods improve specificity but may decrease sensitivity (NIE luciferase immunoprecipitation system assay; sensitivity, 85%; specificity, 100%), and these might not be the best screening methods [20]. In addition, none of the new tests are currently available commercially for use in the United States.

We identified several variables and risk factors associated with increased risk of *S. stercoralis* infection. Analysis of available data concerning country of origin, ethnicity/race, and travel history showed a significant increase in the risk of *S. stercoralis* infection in the Asian population with an OR of 2.7; six of the Asian SSp patients with a documented travel history reported travel outside the United States.

Overall, unlike in previous reports of increased risk of *S. stercoralis* infection in the immigrant population [1, 8], we did not find a difference between SSp and SSn groups with regard to country of origin. This could be owing to missing data in 41% of SSn and 14% of SSp patients. To support our findings, we conducted logistic regression after supplementing missing data with multiple imputation, and this analysis revealed similar results compared with the original analysis. Unfortunately, most of the SSn patients lacked documentation of travel history, which was not routinely documented in the transplant candidates, precluding statistical analysis of this aspect.

We also investigated the relationship between DM and strongyloidiasis because previous reports have suggested contradictory associations. Data from diabetic patients residing in a *Strongyloides*-endemic region indicated an increased risk of infection in these patients (OR, 3.9; 95% CI, 1.6–15.9; *P* < .05) [12]. In contrast, another study of the aboriginal population in Australia found that DM as a factor was inversely associated with *Strongyloides* infection (adjusted OR, 0.39; 95% CI, 0.23–0.67; *P* = .001) [13]. In our studied population, we found a significantly increased risk of strongyloidiasis in diabetic patients (OR, 1.5; 95% CI, 1.1–2.1; *P* = .01).

Eosinophilia was an independent factor associated with strongyloidiasis, as expected, in the multivariate analysis, with an increased OR (1.7; 95% CI, 1.1–2.7; *P* = .01) and with a prevalence of 20% among SSp patients. Therefore, about 80% of SSp patients did not exhibit eosinophilia at the time of screening. Prior studies have reported a prevalence of eosinophilia ranging from 20% to 80% in patients with strongyloidiasis [24, 25]. We hypothesize that several factors could have affected our results, such as the variability in the timings when eosinophil counts were measured, the burden of disease, or differences between acute and chronic strongyloidiasis cases.

Strongyloidiasis can present with diarrhea, abdominal pain, and skin manifestations, but it is often asymptomatic, especially in chronic infections [3]. However, because data shedding light on the frequency of GI symptoms are lacking, we investigated the frequency of such symptoms in the SSp group at the time of screening, and we found that only 9% of our SSp patients reported GI symptoms, mostly chronic or recurrent diarrhea (7%). Therefore, although GI symptoms should be considered when testing for *S. stercoralis*, the majority of patients were not symptomatic.

Among the patients who had 3 consecutive ova and parasite stool tests, only 1 patient (2%), born in Vietnam, had a positive result. Although not all SSp patients underwent ova and parasite stool examination, our data reflected a low yield of this test in our studied population. The low sensitivity of this conventional method has prompted some investigators to use other techniques (agar plate culture, Baermann technique) reported to be more sensitive, but such methods take a long time to obtain results and require trained personnel [3, 26]. Promising new diagnostic tests such as polymerase chain reaction could provide a rapid and reliable result in the future, with reported sensitivity ranging from 56% to 72% [27–29]. Such tests are not yet approved or commercially available for diagnostic use.

All of the patients received ivermectin for strongyloidiasis treatment, which is the most effective available therapy for this condition [30, 31]. There is no specific recommendation regarding how to monitor therapeutic response. Some studies suggest seroconversion (positive to negative) 6–12 months after therapy [32, 33]. However, we did not investigate this aspect in our study because its clinical significance is unknown. The optimal therapeutic regimen for *Strongyloides* in pretransplantation prophylaxis is undetermined. The guidance for a living-kidney transplant donor recommends 200 μg/kg doses either on 2 consecutive days or 2 weeks apart [18]. However, another guideline recommends a regimen that is 2 weeks apart, considering the theoretical advantage in the “autoinfective cycle” of *Strongyloides* [34]. Both regimens seemed to work effectively in multiple previous studies, and no direct comparison between regimens was made in those studies [31]. A 2018 study described the poor efficacy of ivermectin therapy against *Strongyloides*, reporting persistent *Strongyloides* positivity after treatment [35], but these results were questioned owing to a small sample size and significantly high rates of treatment failure [36].

A significant number of our patients (6.8%) had seroconversion (negative to positive) during the study period, which suggests that serial serological screening may be required if the patients stay on the transplant waiting list for prolonged periods. This also raises the question of the optimal frequency of screening and the potential for new exposures before or after transplantation. Furthermore, most of those patients had a notable travel history to endemic regions. However, 3 of 16 patients were born in the United States and had denied any travel history, suggesting indigenous acquisition of *S. stercoralis* infection. Further studies are warranted to address those issues.

Finally, we screened our living donors for strongyloidiasis, but we did not implement this screening among deceased donors. However, a recent study from Miami, Florida, showed a prevalence of 3.9% of strongyloidiasis in the deceased donor
population [37]. The implementation of deceased donor screening should be carefully considered in our area based on endemicity and potential impact on the screening process [19]. As of now, we have not encountered any disseminated or hyperinfection cases in our transplant center since implementing pretransplantation universal screening and ivermectin therapy.

Out study has limitations. First, it had a retrospective design, which could lead to selection bias, and we also encountered missing data; however, we evaluated the latter with statistical analysis using multiple imputation, which did not show any difference from previously concluded results. Second, as discussed above, the currently available tests have some limitation in their sensitivity and specificity for the diagnosis of strongyloidiasis. Finally, our study cannot conclude the superiority of universal serological screening over targeted screening, because it was a noncomparative study. Ideally, a comparative study should be conducted to demonstrate that universal screening decreases the incidence of disseminated infection. However, it would be difficult to conduct owing to the low incidence of disseminated infection. We also lack comprehensive data regarding the general prevalence of Strongyloides in the southern states of the United States, to exclude the possibility of endemicity.

To conclude, we found that 9.9% of screened candidates for kidney transplantation in Houston, Texas, were SSps. No factors effectively predicted this result in our population. The universal screening identified a significant number of SSp patients without epidemiological risk factors, which suggests possible local acquisition of the infection. Serial screening should be considered when patients are expected to have a long wait before transplantation in populations similar to ours.

Supplementary Data

Supplementary materials are available at Open Forum Infectious Diseases online. Consisting of data provided by the authors to benefit the reader, the posted materials are not copyedited and are the sole responsibility of the authors, so questions or comments should be addressed to the corresponding author.

Acknowledgment

Potential conflicts of interest. All authors: No reported conflicts of interest. All authors have submitted the ICMJE Form for Disclosure of Potential Conflicts of Interest. Conflicts that the editors consider relevant to the content of the manuscript have been disclosed.

References

1. Centers for Disease Control and Prevention. Parasites—Strongyloides: Epidemiology & risk factors. 2017. Available at: https://www.cdc.gov/parasites/strongyloides/epi.html. Accessed 31 May 2018.
2. Russell ES, Gray EB, Marshall RE, et al. Prevalence of Strongyloides stercoralis antibodies among a rural Appalachian population—Kentucky, 2013. Am J Trop Med Hyg 2014; 91:1000–1.
3. Roxby AC, Gottlieb GS, Limaye AP. Strongyloidiasis in transplant patients. Clin Infect Dis 2009; 49:1411–23.
4. Hayes J, Nellore A. Management of Strongyloides in solid organ transplant recipients. Infect Dis Clin North Am 2018; 32:79–93.
5. Prendki V, Fenaux P, Durand R, et al. Strongyloidiasis in man 75 years after initial exposure. Emerg Infect Dis 2011; 17:931–2.
6. Lam CS, Tong MKH, Chan KM, Siu YP. Disseminated strongyloidiasis: a retrospective study of clinical course and outcome. Eur J Clin Microbiol Infect Dis 2006; 25:14–8.
7. Link K, Orenstein R. Bacterial complications of strongyloidiasis: Streptococcus bovis meningitis. South Med J 1999; 92:728–31.
8. Schar E, Trostdorf U, Giardina E, et al. Strongyloides stercoralis: global distribution and risk factors. PLoS Negl Trop Dis 2013; 7:e2288.
9. Nera FA, Murphy EL, Gam A, et al. Antibodies to Strongyloides stercoralis in healthy Jamaican carriers of HTLV-I. N Engl J Med 1989; 320:252–3.
10. de Oliveira LCM, Ribeiro CT, Mendes Dde M, et al. Frequency of Strongyloides stercoralis infection in alcoholics. Mem Inst Oswaldo Cruz 2002; 97:119–21.
11. Vazquez Guillamet LJ, Saublitz Z, Mlikovic B, et al. Strongyloides stercoralis infection—human immunodeficiency virus (HIV)-infected patients in the United States of America: a case report and review of literature. Am J Case Rep 2017; 18:339–46.
12. Mendonça SCI, Gonçalves-Pires M do RE, Rodrigues RM, et al. Is there an association between positive Strongyloides stercoralis serology and diabetes mellitus? Acta Trop 2006; 99:102–5.
13. Hays R, Esterman A, Giacomini P, et al. Does Strongyloides stercoralis infection protect against type 2 diabetes in humans? evidence from Australian aboriginal adults. Diabetes Res Clin Pract 2015; 107:355–61.
14. Rodrigues-Hernandez MJ, Ruiz-Perez-Pipoa M, Cañas E, et al. Strongyloides stercoralis hyperinfection transmitted by liver allograft in a transplant recipient. Am J Transplant 2009; 9:2637–40.
15. Abanyie FA, Gray EB, Delli Carpini KW, et al. Donor-derived Strongyloides stercoralis infection in solid organ transplant recipients in the United States, 2009–2013. Am J Transplant 2015; 15:1369–75.
16. Len O, Garzoni C, Lumbreras C, et al. Recommendations for screening of donor and recipient prior to solid organ transplantation and to minimize transmission of donor-derived infections. Clin Microbiol Infect 2014; 20:10–8.
17. Fischer SA, Lu K; AST Infectious Diseases Community of Practice. Screening of donor and recipient in solid organ transplantation. Am J Transplant 2013; 13(suppl 4):9–21.
18. The Organ Procurement and Transplantation Network. Recognizing seasonal and geographically endemic infections in organ donors: considerations during living donor evaluation background. Available at: https://optn.transplant.hrsa.gov/media/1138/seasonal_disease_guidance.pdf. Accessed 30 May 2018.
19. Levi ME, Kumar D, Green M, et al. Considerations for screening live kidney donors for endemic infections: a viewpoint on the UNOS policy. Am J Transplant 2014; 14:1003–11.
20. Bisoofi Z, Buonfante D, Sequi M, et al. Diagnostic accuracy of five serologic tests for Strongyloides stercoralis infection. PLoS Negl Trop Dis 2014; 8:e2640.
21. van Doorn HR, Koelewyn R, Hofvelegen H, et al. Use of enzyme-linked immunosorbent assay and dipstick assay for detection of Strongyloides stercoralis infection in humans. J Clin Microbiol 2007; 45:438–42.
22. Hamilton KW, Abt PL, Rosenbach MA, et al. Donor-derived Strongyloides stercoralis infections in renal transplant recipients. Transplantation 2011; 91:1019–24.
23. Patel G, Arvelakis A, Sauter BV, et al. Strongyloides hyperinfection syndrome after intestinal transplantation. Transpl Infect Dis 2008; 10:137–41.
24. Loutfy MR, Wilson M, Keystone JS, Kain KC. Serology and eosinophil count in the diagnosis and management of strongyloidiasis in a non-endemic area. Am J Trop Med Hyg 2002; 66:749–52.
25. Naidu P, Yanow SK, Kowalewska-Grochowska KT. Eosinophilia: a poor predictor of Strongyloides infection in refugees. Can J Infect Dis Med Microbiol 2013; 24:93–6.
26. Sato Y, Kobayashi I, Toma H, Shiroma Y. Efficacy of stool examination for detection of Strongyloides infection. Am J Trop Med Hyg 1995; 53:248–50.
27. Buonfrate D, Requena-Mendez A, Anghelen E, et al. Accuracy of molecular biology techniques for the diagnosis of Strongyloides stercoralis infection—a systematic review and meta-analysis. PLoS Negl Trop Dis 2018; 12:e006229.
28. Erice A, Graziano M, Viscusi Y, Broncano N, et al. A novel, multi-paradigm, real-time polymerase chain reaction approach for eight gastrointestinal parasites provides improved diagnostic capabilities to resource-limited at-risk populations. Am J Trop Med Hyg 2013; 88:1041–7.
29. Buonfrate D, Formenti F, Perandin F, Bisoofi Z. Novel approaches to the diagnosis of Strongyloides stercoralis infection. Clin Microbiol Infect 2015; 21:543–52.
30. Igual-Adell R, Oltra-Alcaraz C, Soler-Company E, et al. Efficacy and safety of ivermectin and thibendazole in the treatment of strongyloidiasis. Expert Opin Pharmacother 2004; 5:2615–9.
31. Henriquez-Camacho C, Gotuzzo E, Echevarria J, et al. Ivermectin versus albendazole or thibendazole for Strongyloides stercoralis infection. Cochrane Database Syst Rev 2016; CD007745.
32. Salvador F, Sulleiro E, Sánchez-Montalvá A, et al. Usefulness of Strongyloides stercoralis serology in the management of patients with eosinophilia. Am J Trop Med Hyg 2014; 90:830–4.
33. Karunajeewa H, Kelly H, Leslie D, et al. Parasite-specific IgG response and peripheral blood eosinophil count following albendazole treatment for presumed chronic strongyloidiasis. J Travel Med 2006; 13:84–91.
34. Schwartz BS, Mawhorter SD; AST Infectious Diseases Community of Practice. Parasitic infections in solid organ transplantation. Am J Transplant 2013; 13(suppl 4):280–303.
35. Repetto SA, Ruybal P, Batalla E, et al. Strongyloidiasis outside endemic areas: long-term parasitological and clinical follow-up after ivermectin treatment. Clin Infect Dis 2018; 66:1558–65.
36. Buonfrate D, Bisoffi Z. Is ivermectin ineffective for strongyloidiasis? Clin Infect Dis 2018; 67:810–1.
37. Camargo JE, Simkins J, Anjan S, et al. Implementation of a Strongyloides screening strategy in solid organ transplant donors and recipients. Clin Transplant 2019; e13497.